SLUSH

A newly published, peer-reviewed study has used Lumito's SCIZYS tissue-imaging platform to analyse biomarker expression in single immune cells, extending its validated use beyond tissue samples into cell-based research for the first time.

The company is to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company, provisionally named 'Mölnlycke Surgical', while Wound Care and Antiseptics continue as Mölnlycke.

BioArctic's partner Eisai has received Japanese approval for Leqembi Pen, a subcutaneous autoinjector formulation of the Alzheimer's drug Leqembi (lecanemab), making Japan the third country globally to approve the self-administered formulation.

Circio Holding has completed a private placement raising approximately NOK 200 million in gross proceeds, earmarked to accelerate a new in vivo CAR-T cell therapy programme built on the company's circVec circular-RNA platform.

The company's blood-based disease-risk detection has become part of statutory primary healthcare in Finland, as registration opened today for Eloisa's "Wellbeing Gift" programme in the South Savo Wellbeing Services County.

Oxcia has been granted Orphan Drug Designation (ODD) by the FDA for OXC-201, its drug candidate for idiopathic pulmonary fibrosis (IPF), just weeks after a similar decision from the EMA.

A Swedish healthcare delegation traveled to Kyiv on September 2–4 to strengthen cooperation on rebuilding Ukraine's healthcare system, timed to one of the most difficult periods for the city in months.